Form 4 for TAK TAKEDA PHARMACEUTICAL CO LTD

Accepted 2026-04-28 06:08:00 ET · period of report 2026-04-27 · accession 0001395064-26-000138 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-04-28 06:08	2026-04-27	TAK	Furuta Milano	CFO, Dir	A - Grant	$0.00	+7,800	57.9K	+16%	$0
D	2026-04-28 06:08	2026-04-27	TAK	Furuta Milano	CFO, Dir	A - Grant	$0.00	+7,814	16.6K	+89%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2026-04-27	A	A	7,800	$0.00	57,900	D	—	—	(F1) On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of ordinary shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. (F2) Includes 27,300 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4000 shares).
2	Derivative	Tax Obligation Award	2026-04-27	A	A	7,814	$0.00	16,619	D	— · 2026-06-01 to 2026-06-01	7,814 Ordinary Shares	(F3) Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.